Literature DB >> 32500410

Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients.

Sumanth P Reddy1, Jonathan E Dowell2, Edward Pan3.   

Abstract

Patients with small cell lung cancer (SCLC) are more likely to have synchronous brain metastasis (SBM) at the time of diagnosis than patients with any other extracranial primary malignancy. We sought to identify which factors predicted an increased risk of SBM in SCLC as well as which factors affected the prognosis of these patients. 38,956 Patients in the Surveillance, Epidemiology, and End Results (SEER) database with microscopically confirmed SCLC from 2010 to 2016 were identified. 6264 (16.1%) Patients with SCLC had SBM at the time of diagnosis. In the multivariable logistic regression, disease specific factors that were predictive of SBM were primary tumor size > 7 cm (adjusted OR = 1.14, 95% CI [1.02, 1.28], p = 0.02), synchronous lung metastases, and synchronous bone metastases. Demographic specific factors predictive of increased SBM risk in this model were younger age, male sex, and race (American Indian/Alaska Native and black patients). Patients insured through Medicaid were less likely to present with SBM. In the multivariate Cox proportional hazards model, lack of insurance was the strongest predictor of mortality (adjusted HR = 1.47, 95% CI [1.26, 1.73], p < 0.001). Other factors associated with an increased risk of mortality include male sex, older age, health insurance coverage through Medicaid, synchronous liver metastasis, synchronous lung metastasis, and primary tumor size > 7 cm. In contrast, Asian patients had a lower risk of mortality. This study identifies risk factors for SBM among patients with SCLC, as well as indicators of prognosis among this patient population.

Entities:  

Keywords:  CNS; Insurance; Intracranial; Metastasis; Prognosis; SCLC; SEER; Small cell lung cancer; Synchronous

Mesh:

Year:  2020        PMID: 32500410     DOI: 10.1007/s10585-020-10040-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  2 in total

1.  Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer.

Authors:  Saiama N Waqar; Sadaf H Waqar; Kathryn Trinkaus; Carlos A Gadea; Cliff G Robinson; Jeffrey Bradley; Mark A Watson; Varun Puri; Ramaswamy Govindan; Daniel Morgensztern
Journal:  Am J Clin Oncol       Date:  2018-01       Impact factor: 2.339

2.  Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors.

Authors:  Ali Saber; T Jeroen N Hiltermann; Klaas Kok; M Martijn Terpstra; Kim de Lange; Wim Timens; Harry J M Groen; Anke van den Berg
Journal:  Carcinogenesis       Date:  2017-02-01       Impact factor: 4.944

  2 in total
  4 in total

1.  Machine Learning for the Prediction of Synchronous Organ-Specific Metastasis in Patients With Lung Cancer.

Authors:  Huan Gao; Zhi-Yi He; Xing-Li Du; Zheng-Gang Wang; Li Xiang
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

2.  Prophylactic cranial irradiation in patients with small cell lung cancer in The Netherlands: A population-based study.

Authors:  Mathijs L Tomassen; Mieke J Aarts; Max Peters; Anne van Lindert; Dirk K M De Ruysscher; Joost J C Verhoeff; Peter S N van Rossum
Journal:  Clin Transl Radiat Oncol       Date:  2021-02-12

3.  Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.

Authors:  Yonghui Li; Zhenqing Sun; Wei Sun; Haibo Wang; Jinchi Zu
Journal:  Clin Med Insights Oncol       Date:  2022-01-24

4.  Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.

Authors:  Xinqing Lin; Tingting Lu; Haiyi Deng; Chunxin Liu; Yilin Yang; Tao Chen; Yinyin Qin; Xiaohong Xie; Zhanhong Xie; Ming Liu; Ming Ouyang; Shiyue Li; Yong Song; Nanshan Zhong; Wei Qiu; Chengzhi Zhou
Journal:  J Neurol       Date:  2021-07-20       Impact factor: 6.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.